KURA ONCOLOGY, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- KURA ONCOLOGY, INC. stock issued during period, value, stock options exercised for the quarter ending 2021-09-30 was $2.26M, a 53.57% decline year-over-year.
- KURA ONCOLOGY, INC. stock issued during period, value, stock options exercised for the quarter ending 2021-03-31 was $829.00K, a 235.63% increase year-over-year.
- KURA ONCOLOGY, INC. stock issued during period, value, stock options exercised for the quarter ending 2020-09-30 was $4.86M, a 529.92% increase year-over-year.
- KURA ONCOLOGY, INC. stock issued during period, value, stock options exercised for the quarter ending 2020-03-31 was $247.00K, a 142.16% increase year-over-year.
- KURA ONCOLOGY, INC. stock issued during period, value, stock options exercised for fiscal 2017 was $232.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2021-09-30 | $2.26M 10-Q · filed 2021-11-04 | |
| 2021-03-31 | $829.00K 10-Q · filed 2021-05-06 | |
| 2020-09-30 | $4.86M 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $247.00K 10-Q · filed 2021-05-06 | |
| 2019-09-30 | $772.00K 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $102.00K 10-Q · filed 2020-05-04 | |
| 2018-09-30 | $202.00K 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $125.00K 10-Q · filed 2019-08-01 | |
| 2017-12-31 | $232.00K 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |